NanoViricides, Inc. reports on the highly desirable blood concentration profile of its lead clinical stage broad-spectrum antiviral agent NV-387 upon intravenous (I.V.) administration in a non-human primate (NHP) animal model. The Company has found that its lead nanoviricide broad-spectrum antiviral drug candidate NV-387, when given as a slow bolus intravenous infusion, resulted in a relatively flat plateau of blood concentration of the drug with very slow decline over a 24 hour period in a cynomolgus monkey model. The maximum concentration as well as the plateau concentration increased in a dose-dependent manner, as expected.

This sustained drug level in the blood stream for a relatively long period of time enables infrequent dosing. It is the result of the unique polymeric design of NV-387. NV-387 is a "chemical nanomachine".

It is made up of polymer with its size chosen to minimize loss by renal filtration. The observed pharmacokinetic profile of NV-387 supports a once-daily or less frequent dosing regimen. The Company has already developed an injectable formulation of NV-387, namely NV-387 Solution for Injection, Infusion, and Inhalation.

An injection of NV-387 would be useful for moderate to severe illness, especially because of the sustained blood profile that requires infrequent dosing. An infusion would be suitable for severely ill hospitalized patients. Importantly, this NV-387 Solution can be readily delivered directly into the lungs of a patient using a simple handheld nebulizer over a period of a few minutes.

Such delivery can enable direct attack on the virus where such attack is most needed in the cases of severe lung infection. The utility of NV-387 is extremely broad, reminiscent of the utility of antibiotics.